Trial Ruxolitinib and Peg-interferon Alpha-2a Combination in Patients With Primary Myelofibrosis RUXOPeg

NCT02742324 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

37

Enrollment

OTHER

Sponsor class

Conditions

Myelofibrosis

Interventions

DRUG: Ruxolotinib
DRUG: peg-IFN alpha -2a

Sponsor

French Innovative Leukemia Organisation